Radiotheranostics Market - Top Companies and Manufacturers

In the News

• TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.
• Clarity Pharmaceuticals announced that the first patient in its phase1/2theranostic trial, which is testing 64Cu/67Cu SAR-bisPSMA theranostic product in people with metastatic castrate-restant prostate cancer, has been given a dose. The promising preclinical and clinical result so far support clarity’s investigation of the optimised SAR-bisPSMA product in additional oncology indications where the theranostic approach may be useful.